首页>
外文期刊>current opinion in urology
>MAB using LHRH agonist Buserelin in combination with shortdash;term (two weeks) or longdash;term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer
【24h】
MAB using LHRH agonist Buserelin in combination with shortdash;term (two weeks) or longdash;term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer
展开▼
机译:MAB using LHRH agonist Buserelin in combination with shortdash;term (two weeks) or longdash;term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer